Evidence map›Paper›PMID 32458204›Full record

ArticleJournal of molecular neuroscience : MN2020

Human VGF-Derived Antidepressant Neuropeptide TLQP62 Promotes SH-SY5Y Neurite Outgrowth.

Daniela Moutinho, Sónia Veiga, Jesús R Requena

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Nanoscale advances · 2024
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Daniela MoutinhoCiMUS Biomedical Research Institute, IDIS, University of Santiago de Compostela, Room SS1D, Avenida de Barcelona s/n, 15782, Santiago de Compostela, Spain.
Sónia VeigaCiMUS Biomedical Research Institute, IDIS, University of Santiago de Compostela, Room SS1D, Avenida de Barcelona s/n, 15782, Santiago de Compostela, Spain.
Jesús R RequenaCiMUS Biomedical Research Institute, IDIS, University of Santiago de Compostela, Room SS1D, Avenida de Barcelona s/n, 15782, Santiago de Compostela, Spain. jesus.requena@usc.es.
Center for Research in Molecular Medicine and Chronic Diseases · ESUniversidade de Santiago de Compostela · ES

Funding

FP7 People: Marie-Curie Actions FP7-PEOPLE-2013-ITN
6 · The paper itself

Abstract

TLQP62 is a neuropeptide derived from the neurotrophin-inducible VGF (non-acronymic) protein with antidepressant-like properties capable of inducing increased memory on the mouse hippocampus by promoting neurogenesis and synaptic plasticity through brain-derived neurotropic factor (BDNF) and its receptor tyrosine receptor kinase B (TrkB). Human SH-SY5Y neuroblastoma-derived cell line is widely used in neuroscience research and is known to undergo neurodifferentiation in the presence of all-trans retinoic acid by upregulating the expression of TrkB, making cells responsive to BDNF. As TLQP62 promotes BDNF expression, which in turn activates a BDNF/TrkB/CREB (cAMP response element-binding protein) pathway that upregulates VGF expression, there is a VGF-BDNF regulatory loop that seems to regulate neurogenesis. Therefore, here, we evaluate by morphological observation the ability of human TLQP62 to induce neuritogenesis of human SH-SY5Y neuroblastoma-derived cell line in a retinoic acid and BDFN-like way, making this cell line a suitable cell model for further studies concerning TLQP62 molecular mechanisms and signalling pathways. SIGNIFICANCE STATEMENT: VGF has been widely explored for its role in emotional behaviour and neuropsychiatric illness (Bartolomucci et al. 2011). Although VGF levels were found reduced in leukocytes of depressed patients, after antidepressant treatment or voluntary exercise, those levels were found to be restored in the hippocampus (Hunsberger et al. 2007; Thakker-Varia et al. 2007). Administration to hippocampal cells of TLQP62 produced an increase in synaptic charge that could explain this antidepressants effects (Alder et al. 2003). This interesting role of TLQP62 in the brain, especially in the hippocampus, makes this neuropeptide an attractive target for further investigation of its role in neurogenesis, learning, memory, and neurological disorders, and possible treatment development. Thus, the identification of a receptor(s) for this peptide and associated signalling pathway(s) is of high importance, as well as a proper cell model to perform those studies.

Indexed as

Brain-Derived Neurotrophic FactorCell Line, TumorCyclic AMP Response Element-Binding ProteinHumansMembrane GlycoproteinsNerve Growth FactorsNeuronal OutgrowthPeptidesReceptor, trkBSignal TransductionBrain-Derived Neurotrophic FactorCyclic AMP Response Element-Binding ProteinMembrane GlycoproteinsNerve Growth FactorsPeptidesReceptor, trkBTLQP62 peptidetropomyosin-related kinase-B, humanVGF protein, humanNeurodifferentiationRASH-SY5YTLQP62VGF

Identifiers

PMID32458204
OpenAlexW3030688374

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.